Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...
Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback